H.C. Wainwright & Co.

The firm rebuilt itself during the 1990s after a period of financial instability, choosing the micro-cap healthcare niche because bulge-bracket banks were exiting it. Life sciences companies below a $500 million market cap need equity research coverage, institutional sales support, and banking services — but cannot interest the largest investment banks that require larger fee pools per deal. H.C. Wainwright bundles all three functions under one roof and derives its economics from transaction fees on repeated follow-on offerings for a concentrated issuer base.

The firm primarily acts as a bookrunner or placement agent on public and private securities offerings — follow-on public offerings, registered direct offerings, confidentially marketed public offerings, and private placements. It also provides strategic advisory services, but its disclosed revenue stream emphasizes transaction fees from capital raises. The firm does not disclose managing an internal fund or proprietary balance-sheet investment portfolio; it is a fee-based intermediary, not an allocator.

The equity research platform is the top of the funnel. The firm publishes company-initiated research across over 400 names — predominantly small-cap biotechnology, pharmaceutical, and medical-device companies. That research coverage creates relationships with management teams and generates corporate access opportunities. Banking mandates often begin with a research initiation and progress to follow-on financings over multiple years. The model depends on long-duration issuer relationships rather than competitive auction-style pitches.

Mark Viklund serves as Chief Executive Officer, and Edward D. Silvera serves as Chief Operating Officer (per the firm's official communications). The firm's parent entity is H.C. Wainwright Holdings, Inc., which is publicly traded, but day-to-day investment banking leadership and key decision rights on deal execution rest with the senior management team that has guided the firm since its post-1990s restructuring.

Public record does not identify a dedicated balance-sheet investment vehicle or proprietary capital deployment arm. The firm appears to operate as a pure agency investment bank, earning placement fees and underwriting discounts rather than making principal investments. Any balance-sheet exposure likely relates to the trading desk's market-making and inventory function for micro-cap healthcare names rather than long-term principal deployment.

The firm's primary coverage includes biotechnology, specialty pharmaceuticals, and medical technology. In recent years it has broadened modestly into technology and cleantech via its research and banking platforms, but healthcare names remain the dominant source of disclosed underwriting mandates and research coverage. The firm does not cover consumer, industrials, or financials in any material disclosed capacity.

Yes — the direct corporate lineage traces to the 1868 Boston partnership founded by Henry C. Wainwright. The original partnership underwrote railroad and industrial bonds before eventually moving to New York and undergoing multiple ownership transitions. The modern entity operates under a holding company structure (H.C. Wainwright Holdings, Inc.), but has continuously carried the Wainwright name throughout its more than 150-year history.